Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
LA JOLLA, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new EQ504 preclinical data have been accepted for poster presentations at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists taking place in Boston, Massachusetts, April 15-19, 2026. “We are excited to share these preclinical findings that support the differentiated profile of EQ504 as a potent AhR modulator, with the potential to influence both immune cell responses and barrier restoration,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “Together, these attributes are particularly important in diseases such as ulcerative colitis, where both reducing inflammation and improving mucosal healing are critical to achieving meaningful outcomes for patients.” Details of the presentations: Abstract title: EQ504: A Novel AhR Modulat
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Equillium (EQ) is now covered by B. Riley Financial, Inc.. They set a "buy" rating and a $6.00 price target on the stock.MarketBeat
- Equillium (EQ) was given a new $6.00 price target by Raymond James Financial, Inc.. They now have a "strong-buy" rating on the stock.MarketBeat
- Equillium (EQ) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $10.00 price target on the stock.MarketBeat
- Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Equillium GAAP EPS of -$0.04 beats by $0.02, revenue of $0M [Seeking Alpha]Seeking Alpha
EQ
Sec Filings
- 4/15/26 - Form ARS
- 4/15/26 - Form DEFA14A
- 4/15/26 - Form DEF
- EQ's page on the SEC website